Company intelligence / Profile preview
Base Therapeutics (Shanghai) Co., Ltd.
- Ownership
- Private
- Development stage
- Other
Overview
Base Therapeutics is the first company to receive both Chinese and US IND approval for a base-edited universal NK cell therapy (NK510) for solid tumors as of November 2024. Early preclinical and clinical studies show strong anti-tumor activity and high editing efficiency (>90%) using the proprietary AccuBase® base editing platform. Additional cell and gene therapies targeting genetic and autoimmune diseases are in earlier development.
- Therapeutic areas
- OncologyMetabolic DisordersImmunologyRare Diseases
- Modalities
- Base editingCell therapyGene therapyMonoclonal antibody
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Base Therapeutics (Shanghai) Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Base Therapeutics (Shanghai) Co., Ltd..